Name: HER2 Antibody
Brand: Molecular Depot
SKU: L2002877
Price: 695 USD
Availability: InStock
Rating: 5 (1 reviews)

Sale!

HER2 Antibody

Original price was: $1,395.00.Current price is: $695.00.

Catalog Number: L2002877 (100 ug)
This HER2 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between amino acids from the human region of human HER2. This antibody is polyclonal and of the Rabbit Ig isotype. Its species reactivity is: Human, Mouse. Purification: Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. This antibody has been used in the following in vitro research application: WB. Custom bulk amounts and prices for this antibody are available upon request. Enquire live about this product at: Live Chat.

In stock

SKU: L2002877 Categories: Antibodies, Biochemistry Tag: MD 1000

Product Description

5/5 - (1 vote)

HER2 Antibody
Catalog number: L2002877
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 ug
Molecular Weight or Concentration: 0.25-0.5 mg/mL
Supplied as: Solution
Applications: a molecular tool for various biochemical applications
Storage: -20°C
Keywords: Receptor tyrosine-protein kinase erbB-2, 2.7.10.1, Metastatic lymph node gene 19 protein, MLN 19, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, CD340, ERBB2, HER2, MLN19, NEU, NGL
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1. Slamon, D. J., et al. (2001). “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.” *New England Journal of Medicine*, 344(11), 783-792.

2. Baselga, J., et al. (2012). “Trastuzumab in combination with chemotherapy for HER2-positive breast cancer: a review of the clinical data.” *Clinical Cancer Research*, 18(24), 6406-6412.

3. Gianni, L., et al. (2010). “Treatment with trastuzumab alone or in combination with chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis.” *The Lancet Oncology*, 11(3), 227-238.

4. Swain, S. M., et al. (2015). “Pertuzumab, trastuzumab, and docetaxel in HER2-positive breast cancer.” *New England Journal of Medicine*, 372(3), 197-207.

5. Moasser, M. M. (2007). “The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.” *Oncogene*, 26(45), 6469-6487.

6. Burstein, H. J., et al. (2019). “Therapeutic approaches to targeting HER2-positive breast cancer.” *Nature Reviews Clinical Oncology*, 16(2), 85-99.

7. Krop, I. E., et al. (2010). “A phase II study of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer who have previously received trastuzumab and a taxane.” *Clinical Cancer Research*, 16(9), 2630-2637.

8. Chen, D. S., et al. (2016). “HER2-targeted therapies: mechanisms of action and resistance in breast cancer.” *Nature Reviews Clinical Oncology*, 13(6), 392-404.

9. Spector, N. L., et al. (2007). “The role of HER2 in breast cancer: a review of the literature and clinical implications.” *Clinical Breast Cancer*, 7(5), 353-360.

10. Hynes, N. E., & Lane, H. A. (2005). “ErbB receptors and cancer.” *European Journal of Cancer*, 41(13), 2065-2070.
HER2 Antibody

Products Related to HER2 Antibody can be found at Antibodies